In:
Pulmonary Circulation, Wiley, Vol. 6, No. 3 ( 2016-09), p. 261-273
Abstract:
Pulmonary arterial hypertension (PAH) is a multifactorial disease characterized by interplay of many cellular, molecular, and genetic events that lead to excessive proliferation of pulmonary cells, including smooth muscle and endothelial cells; inflammation; and extracellular matrix remodeling. Abnormal vascular changes and structural remodeling associated with PAH culminate in vasoconstriction and obstruction of pulmonary arteries, contributing to increased pulmonary vascular resistance, pulmonary hypertension, and right ventricular failure. The complex molecular mechanisms involved in the pathobiology of PAH are the limiting factors in the development of potential therapeutic interventions for PAH. Over the years, our group and others have demonstrated the critical implication of lipids in the pathogenesis of PAH. This review specifically focuses on the current understanding of the role of oxidized lipids, lipid metabolism, peroxidation, and oxidative stress in the progression of PAH. This review also discusses the relevance of apolipoprotein A‐I mimetic peptides and microRNA‐193, which are known to regulate the levels of oxidized lipids, as potential therapeutics in PAH.
Type of Medium:
Online Resource
ISSN:
2045-8940
,
2045-8940
Language:
English
Publisher:
Wiley
Publication Date:
2016
detail.hit.zdb_id:
2638089-4
